1103-OR: GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1103-or ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von HANNE HAAHR und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction and Objective: Urocortin-2 (UCN2), an endogenous agonist of corticotropin-releasing hormone receptor 2 (CRHR2), plays an important role in regulating muscle mass, energy balance and glucose metabolism. Here, we evaluated GUB-UCN2, a potent long-acting CRHR2-selective UCN2 analogue, as monotherapy and in combination with semaglutide, in aged diet-induced obese (DIO) rats.
Methods
5-week-old DIO rats, pre-fed a high-fat diet for 24 weeks, received (SC, QD) vehicle, GUB-UCN2 (low and medium dose, respectively), semaglutide (10 nmol/kg), or GUB-UCN2 and semaglutide co-treatment for 12 weeks. Other DIO rats were pretreated with semaglutide for 3 weeks before switching to GUB-UCN2 combination therapy for additional 9 weeks.
Results
Compared to vehicle, 12 weeks of GUB-UCN2 treatment increased whole-body lean mass by ≈+14% (both doses) and reduced whole-body fat mass by -22% (low dose) and -33% (medium dose), whereas semaglutide reduced both lean (-3%) and fat mass (-20%). When combined with semaglutide, GUB-UCN2 preserved and increased lean mass (~+8%) while amplifying fat mass loss (-48% to -55%) with maintained body weight loss. GUB-UCN2 increased soleus muscle weight (+25-29%), volume (+29%), and cross-sectional area (+21-24%), and reduced intramyocellular lipid content (-41% to -57%). GUB-UCN2, both as monotherapy and in combination with semaglutide, produced more robust improvements in glucose, insulin, leptin, and triglycerides than semaglutide alone.
Conclusion
GUB-UCN2 monotherapy increased lean and muscle mass while reducing fat mass in aged DIO rats. In combination with semaglutide, GUB-UCN2 preserved and expanded lean and muscle mass during weight loss, further enhanced fat mass reduction, and improved glycemic control and lipid profiles. These results support GUB-UCN2 as a promising therapeutic candidate to preserve and expand muscle mass and enhance fat loss, alone or in combination with GLP-1 receptor agonist therapies. Disclosure H. Haahr: Employee; Current; Gubra. Stock/Shareholder; Current; Novo Nordisk A/S. T. Porsgaard: None. M. Hahn: Employee; Current; Gubra. A.K. Sárvári: None. C. Hjørringgaard: Employee; Current; Gubra. S.T. Bak: None. H.H. Hansen: Employee; Current; Gubra. L. Thisted: None. L.H. Kruse: None. L. Dalbøge: None.
Zitieren
APA
HAAHR, H., PORSGAARD, T., HAHN, M., SÁRVÁRI, A. K., HJØRRINGGAARD, C., BAK, S. T., HANSEN, H. H., THISTED, L., KRUSE, L. H., & DALBØGE, L. S. (2026). 1103-OR: GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1103-or
Vancouver
HAAHR H, PORSGAARD T, HAHN M, SÁRVÁRI AK, HJØRRINGGAARD C, BAK ST, et al. 1103-OR: GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1103-or
BibTeX
@article{HAAHR2026,
author = {HAAHR, HANNE and PORSGAARD, TRINE and HAHN, MAX and SÁRVÁRI, ANITTA K. and HJØRRINGGAARD, CLAUDIA and BAK, STINE T. and HANSEN, HENRIK H. and THISTED, LOUISE and KRUSE, LOUISE H. and DALBØGE, LOUISE S},
title = {1103-OR: GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1103-or}
}
EUVIMED